Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical Trial in Chronic Hepatitis D at EASL 2024 Congress

100% of treated patients in Arm 1 achieved virologic response by Week 28

Most patients also achieved ALT normalization and composite response

BJT-778 was well tolerated across all arms at doses up to 900mg

Excerpt from the Press Release:

SAN MATEO, Calif., June 05, 2024 (GLOBE NEWSWIRE) — Bluejay Therapeutics, a private clinical-stage biopharmaceutical company focused on viral and liver diseases, today announced positive preliminary data from the Phase 2 study of BJT-778, a fully human IgG1 monoclonal antibody that acts against hepatitis B surface antigen (anti-HBsAg mAb), in patients with chronic hepatitis D (CHD). The data were presented in a late-breaking poster at the European Association for the Study of the Liver (EASL) Congress 2024.

In the first test arm, 100% of treated patients achieved a virologic response (at least a 2 log reduction in hepatitis D virus (HDV) RNA or becoming HDV RNA undetectable) by Week 28 while receiving treatment with BJT-778. All subjects had reductions of alanine aminotransferase (ALT) from baseline, including two-thirds of subjects whose ALT became normal, reflecting a beneficial effect on liver inflammation. These results highlight the potential of BJT-778 as a monotherapy treatment for CHD.

“We are pleased to present the first look at the safety and clinical activity of BJT-778, which supports the potential for BJT-778 to address unmet needs for the millions of people in the world living with chronic hepatitis D,” said Dr. Keting Chu, Founder and CEO of Bluejay.

Click the button below to read the entire Press Release:

Continue Reading The Press Release